Pharmacogenomics of COVID-19 therapies
Review Article
[키워드] ABCC2
adverse effects
Alter
association
Baricitinib
Chloroquine
clinical
Concentration
coronavirus disease
Corticosteroids
COVID-19
COVID-19 patient
CYP2C8
CYP2D6
drug
Effect
Efficacy
Efficacy and safety
Evidence
Favipiravir
FDA
food
genetic marker
Genetic markers
genetic variants
global pandemic
Hemolysis
high mortality
Hydroxychloroquine
hydroxychloroquine/chloroquine
information
inhibitors
interferon
Interferon beta-1b
labeling
liver
morbidity
notable
other variants
pharmacogenetics
pharmacogenomics
QT prolongation
Remdesivir
ribavirin
risk
ruxolitinib
searched
SLC28A2
SLC29A1
SLCO1A2
SLCO1B1
Therapies
therapy
Tocilizumab
Toxicity
variant
viral infection
website
[DOI] 10.1038/s41525-020-00143-y PMC 바로가기 [Article Type] Review Article
[DOI] 10.1038/s41525-020-00143-y PMC 바로가기 [Article Type] Review Article